ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 297 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,953,914 | -23.7% | 184,366 | +1.3% | 0.01% | -22.2% |
| Q2 2023 | $6,488,765 | +40.4% | 181,962 | 0.0% | 0.01% | +28.6% |
| Q1 2023 | $4,621,835 | -37.4% | 181,962 | 0.0% | 0.01% | -41.7% |
| Q4 2022 | $7,380,379 | +27.2% | 181,962 | +3.6% | 0.01% | +20.0% |
| Q3 2022 | $5,803,000 | +53.8% | 175,592 | +63.9% | 0.01% | +66.7% |
| Q2 2022 | $3,772,000 | -54.8% | 107,115 | -41.4% | 0.01% | -45.5% |
| Q1 2022 | $8,339,000 | +36.6% | 182,904 | +98.6% | 0.01% | +37.5% |
| Q4 2021 | $6,105,000 | +41.6% | 92,085 | +33.4% | 0.01% | +14.3% |
| Q3 2021 | $4,310,000 | +1.3% | 69,036 | +34.3% | 0.01% | +40.0% |
| Q2 2021 | $4,256,000 | +13.4% | 51,392 | -9.2% | 0.01% | 0.0% |
| Q1 2021 | $3,753,000 | -64.1% | 56,599 | -58.5% | 0.01% | -28.6% |
| Q4 2020 | $10,454,000 | +253.5% | 136,236 | +101.9% | 0.01% | +40.0% |
| Q3 2020 | $2,957,000 | -1.5% | 67,484 | -2.9% | 0.01% | 0.0% |
| Q2 2020 | $3,002,000 | +49.3% | 69,497 | 0.0% | 0.01% | +25.0% |
| Q1 2020 | $2,011,000 | – | 69,497 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |